2025
June
PSGL-1: a novel immune checkpoint for phagocytosis
June 25, 2025
Tumor cells can evade immune detection through a wide range of mechanisms, not all of which are fully understood. In recent work by Zhong and Wang et al., P-selectin glycoprotein ligand 1 (PSGL-1) – a known molecule involved in adhesion, leukocyte trafficking, extracellular vesical generation, and T cell exhaustion – was identified as...
Dimming IFN signaling to brighten CAR-T persistence and efficacy
June 18, 2025
While CAR T cell therapy has shown great success in hematological cancers, relapses may occur, and the therapy has so far shown limited efficacy in solid tumors. Based on their previous data, which showed that genetic deletion of IFNγ in CD19 CAR T cells results in fewer toxicities and better expansion, Bailey, Takei...
A new off-the-shelf CAR T cell product made from iPSCs
June 11, 2025
CAR T cell therapies are well known for their potent capacity for killing antigen-expressing target cells. However, they are often hindered by factors in solid tumors and by challenges related to the development of an autologous T cell product. In order to overcome these hurdles and improve CAR T cell therapies, Hosking et...
Non-mutated tumor antigens in the spotlight for therapeutic targeting
June 4, 2025
Recent discoveries of unmutated aberrantly expressed tumor-specific antigens (aeTSAs) derived from non-coding regions and embryonic transcriptional programs has garnered attention as targets for immunotherapy. Apavaloaei et al. explored cell surface presentation of peptide:MHCs derived from mutated and unmutated tumor antigens (TAs) in melanoma and non-small cell lung cancer (NSCLC), cancer types with high...
